Subscribe to RSS
DOI: 10.1055/s-0045-1807739
2024 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards
Welcome to the latest of our Eberhard F. Mammen award announcements. As noted many times previously, Thieme, the publisher of Seminars in Thrombosis & Hemostasis (STH), has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard Mammen ([Fig. 1]), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades (see [Table 1] for relevant Editorials related to past awards). These awards began in 2009, under two categories; the current award details and conditions are as follows:
-
Most popular article awards: awarded to the authors of the most popular articles published in STH in the preceding 2 years as captured in the preceding year. The awards are determined by the Editor in Chief on the basis of user statistics from Thieme e-Journals. Prefaces, Errata, Letters to the Editor, Editorials, Commentaries, and previous award-winning articles are excluded from further consideration of these awards, which currently comprise two categories—one for “Free Access” articles, and another for a “General Category.” There are two major cash prizes of US$1,000 for each category. In addition, winners of the “General Category” awards are granted “Free Access” status for these articles thereafter.
-
Young investigator awards: best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen; up to six cash prizes of US$1,000 in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation (or as otherwise agreed) for publication in STH. Previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the senior editors of STH. Any potential conflicts of interest are managed by first identifying these, and then excluding those with potential conflicts from voting. Finally, given the increased potential of virtual meetings, virtual presentations can also be considered for the award.
Further details of the awards and the award winners are posted online (https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077), and previous award winner announcements are also available in print (see [Table 1] for a listing of relevant editorials published in this journal as related to the initiation of the Eberhard F. Mammen awards, as well as previous award announcements; these publications are also available for free download from the journal Web site: https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077.
The winners of the 2024 Eberhard F. Mammen awards for the most popular articles from STH for the period of 2022 to 2023 inclusive were announced in an earlier issue of the journal,[1] as were the 2025 Eberhard F. Mammen awards for the most popular articles from STH for the period of 2023 to 2024 inclusive.[2] It is therefore with great pleasure that we would like to announce the winners of the latest round of Young Investigator Awards.
As mentioned above, the Young Investigator Awards represent winners of the best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting (virtual meetings permissible) on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. There are additional considerations, given that the nominees' presentations are not necessarily seen by all of the possible award nominators, being drawn from the broader editorial team of the journal as well as potentially from outside the editorial team, nor necessarily seen by all the voting team (comprising the senior editors of the journal). The latest winners are identified below, with a running list of previous awardees, and the resulting publications in the journal, given in [Table 2]. The latest awardees were derived from presentations at recent meetings of the International Society on Thrombosis and Haemostasis (ISTH).
|
Awardee |
Year awarded |
Publication arising |
|---|---|---|
|
Willem M. Lijfering |
2009 |
Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost. 2011 Nov;37(8):885–896. |
|
Salley Pels |
2009 |
Pels SG. Current therapies in primary immune thrombocytopenia. Semin Thromb Hemost. 2011 Sep;37(6):621–630. |
|
Adam Cuker |
2010 |
Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. Semin Thromb Hemost. 2012 Feb;38(1):31–37. |
|
Giridhara Rao Jayandharan |
2010 |
Jayandharan GR, Srivastava A, Srivastava A. Role of molecular genetics in hemophilia: from diagnosis to therapy. Semin Thromb Hemost. 2012 Feb;38(1):64–78. |
|
Timea Szanto |
2010 |
Szántó T, Joutsi-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand disease and platelet function. Semin Thromb Hemost. 2012 Feb;38(1):55–63. |
|
Birgitta Salmela |
2010 |
Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost. 2012 Feb;38(1):23–30. |
|
Pia Riittaa-Maria Siljander |
2010 |
Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin Thromb Hemost. 2012 Feb;38(1):102–113. |
|
Romaric Lacroix |
2011 |
Lacroix R, Dignat-George F. Microparticles: new protagonists in pericellular and intravascular proteolysis. Semin Thromb Hemost. 2013 Feb;39(1):33–39. |
|
Brad McEwen |
2011 |
McEwen BJ, Morel-Kopp MC, Chen W, Tofler GH, Ward CM. Effects of omega-3 polyunsaturated fatty acids on platelet function in healthy subjects and subjects with cardiovascular disease. Semin Thromb Hemost. 2013 Feb;39(1):25–32. |
|
Neil A. Goldenberg |
2011 |
Bernard TJ, Armstrong-Wells J, Goldenberg NA. The institution-based prospective inception cohort study: design, implementation, and quality assurance in pediatric thrombosis and stroke research. Semin Thromb Hemost. 2013 Feb;39(1):10–14. |
|
Vivien Chen |
2011 |
Chen VM. Tissue factor de-encryption, thrombus formation, and thiol-disulfide exchange. Semin Thromb Hemost. 2013 Feb;39(1):40–47. |
|
Joseph E. Italiano, Jr. |
2011 |
Italiano JE Jr. Unraveling mechanisms that control platelet production. Semin Thromb Hemost. 2013 Feb;39(1):15–24. |
|
Vivian Xiaoyan Du |
2012/2013 |
Du VX, Huskens D, Maas C, Al Dieri R, de Groot PG, de Laat B. New insights into the role of erythrocytes in thrombus formation. Semin Thromb Hemost. 2014 Feb;40(1):72–80. |
|
Andrew Yee |
2012/2013 |
Yee A, Kretz CA. Von Willebrand factor: form for function. Semin Thromb Hemost. 2014 Feb;40(1):17–27. |
|
Sarah O'Brien |
2012/2013 |
O'Brien SH. Contraception-related venous thromboembolism in adolescents. Semin Thromb Hemost. 2014 Feb;40(1):66–71. |
|
Veronica Flood |
2012/2013 |
Flood VH. Perils, problems, and progress in laboratory diagnosis of von Willebrand disease. Semin Thromb Hemost. 2014 Feb;40(1):41–48. |
|
Julie Tange |
2012/2013 |
Tange JI, Grill D, Koch CD, Ybabez RJ, Krekelberg BJ, Fylling KA, Wiese CR, Baumann NA, Block DR, Karon BS, Chen D, Pruthi RK. Local verification and assignment of mean normal prothrombin time and international sensitivity index values across various instruments: recent experience and outcome from North America. Semin Thromb Hemost. 2014 Feb;40(1):115–120. |
|
Kent Chapman |
2012/2013 |
Chapman K, Yuen S. Therapy for thrombotic thrombocytopenia purpura: past, present, and future. Semin Thromb Hemost. 2014 Feb;40(1):34–40. |
|
Andreas Tiede |
2014 |
Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia a: limitations, consequences, and challenges. Semin Thromb Hemost. 2014 Oct;40(7):803–811 |
|
Wendy Lim |
2014 |
Lim W. Thrombotic risk in the antiphospholipid syndrome. Semin Thromb Hemost. 2014 Oct;40(7):741–746. |
|
Susana Nobre Fernandes |
2014 |
Fernandes S, Carvalho M, Lopes M, Araújo F. Impact of an individualized prophylaxis approach on young adults with severe hemophilia. Semin Thromb Hemost. 2014 Oct;40(7):785–789. |
|
Maria Elisa Mancuso |
2014 |
Mancuso ME, Fasulo MR. Thrombin generation assay as a laboratory monitoring tool during by-passing therapy in patients with hemophilia and inhibitors. Semin Thromb Hemost. 2016 Feb;42(1):30–35. |
|
Coen Maas |
2014 |
Tersteeg C, Fijnheer R, Deforche L, Pasterkamp G, de Groot PG, Vanhoorelbeke K, de Maat S, Maas C. Keeping von Willebrand factor under control: alternatives for ADAMTS13. Semin Thromb Hemost. 2016 Feb;42(1):9–17. |
|
Riten Kumar |
2014 |
Kumar R, Dunn A, Carcao M. Changing paradigm of hemophilia management: extended half-life factor concentrates and gene therapy. Semin Thromb Hemost. 2016 Feb;42(1):18–29. |
|
Juraj Sokol |
2015 |
Sokol J, Skerenova M, Jedinakova Z, Simurda T, Skornova I, Stasko J, Kubisz P. Progress in the understanding of sticky platelet syndrome. Semin Thromb Hemost 2017;43(1):8–13 |
|
Ljubica Jovanović |
2015 |
Jovanovic L, Antonijevic N, Novakovic T, Savic N, Terzic B, Zivkovic I, Radovanovic N, Asanin M. Practical aspects of monitoring of antiplatelet therapy. Semin Thromb Hemost 2017;43(1):14–23 |
|
Lucia Stanciakova |
2015 |
Stanciakova L, Dobrotova M, Jedinakova Z, Duraj L, Skornova I, Korinkova L, Holly P, Danko J, Stasko J, Kubisz P. Monitoring of hemostasis and management of anticoagulant thromboprophylaxis in pregnant women with increased risk of fetal loss. Semin Thromb Hemost. 2016 Sep;42(6):612–621. |
|
Tina Biss |
2015 |
Biss TT. Venous thromboembolism in children: is it preventable? Semin Thromb Hemost. 2016 Sep;42(6):603–611. |
|
Tobias Fuchs |
2015 |
Jiménez-Alcázar M, Kim N, Fuchs TA. Circulating extracellular DNA: cause or consequence of thrombosis? Semin Thromb Hemost. 2017 Sep;43(6):553–561 |
|
Jonathan M. Coutinho |
2015 |
Silvis SM, Middeldorp S, Zuurbier SM, Cannegieter SC, Coutinho JM. Risk factors for cerebral venous thrombosis. Semin Thromb Hemost. 2016 Sep;42(6):622–631. |
|
Soundarya Selvam |
2016 |
Selvam S, James P. Angiodysplasia in von Willebrand disease: understanding the clinical and basic science. Semin Thromb Hemost. 2017 Sep;43(6):572–580. |
|
Vincent Muczynski |
2016 |
Muczynski V, Christophe OD, Denis CV, Lenting PJ. Emerging therapeutic strategies in the treatment of hemophilia A. Semin Thromb Hemost. 2017 Sep;43(6):581–590. |
|
Karen Schreiber |
2016 |
Schreiber K, Breen K, Cohen H, Jacobsen S, Middeldorp S, Pavord S, Regan L, Roccatello D, Robinson SE, Sciascia S, Seed PT, Watkins L, Hunt BJ. HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost. 2017 Sep;43(6):562–571. |
|
Jasmine Wee Ting Tay |
2016 |
Tay J, Tiao J, Hughes Q, Jorritsma J, Gilmore G, Baker R. Circulating MicroRNA as thrombosis sentinels: caveats and considerations. Semin Thromb Hemost. 2018 Apr;44(3):206–215. |
|
Adi J. Klil-Drori |
2016 |
Klil-Drori AJ, Tagalakis V. Direct oral anticoagulants in end-stage renal disease. Semin Thromb Hemost. 2018 Jun;44(4):353–363. |
|
Ivar van Asten |
2017 |
van Asten I, Schutgens REG, Urbanus RT. Toward flow cytometry based platelet function diagnostics. Semin Thromb Hemost. 2018 Apr;44(3):197–205. |
|
Elodie Laridan |
2017 |
Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost. 2019 Feb;45(1):86–93. |
|
Leonardo Pasalic |
2017 |
Blennerhassett R, Curnow J, Pasalic L. Immune-mediated thrombotic thrombocytopenic purpura: a narrative review of diagnosis and treatment in adults. Semin Thromb Hemost. 2020 Apr;46(3):289–301 |
|
Yvonne Brennan |
2017 |
Brennan Y, Favaloro EJ, Curnow J. To maintain or cease non-vitamin K antagonist oral anticoagulants prior to minimal bleeding risk procedures: a review of evidence and recommendations. Semin Thromb Hemost. 2019 Mar;45(2):171–179. |
|
Mark Schreuder |
2018 |
Schreuder M, Reitsma PH, Bos MHA. Reversal agents for the direct factor Xa inhibitors: biochemical mechanisms of current and newly emerging therapies. Semin Thromb Hemost. 2020 Nov;46(8):986–998 |
|
James McFadyen |
2018 |
Stevens H, McFadyen JD. Platelets as central actors in thrombosis-reprising an old role and defining a new character. Semin Thromb Hemost. 2019 Nov;45(8):802–809. |
|
David Rabbolini |
2018 |
Mason GA, Rabbolini DJ. The current role of platelet function testing in clinical practice. Semin Thromb Hemost. 2021 Oct;47(7):843–854. |
|
Janka Zolkova |
2018 |
Zolkova J, Sokol J, Simurda T, Vadelova L, Snahnicanova Z, Loderer D, Dobrotova M, Ivankova J, Skornova I, Lasabova Z, Kubisz P, Stasko J. Genetic background of von Willebrand disease: history, current state and future perspectives. Semin Thromb Hemost. 2020 Jun;46(4):484–500 |
|
Tomáš Bolek |
2018 |
Bolek T, Samoš M, Škorňová I, Galajda P, Staško J, Kubisz P, Mokáň M. Proton pump inhibitors and dabigatran therapy: impact on gastric bleeding and dabigatran plasma levels. Semin Thromb Hemost. 2019 Nov;45(8):846–850. |
|
Fraser Macrae |
2018 |
Kearney KJ, Ariëns RAS, Macrae FL. The role of fibrin(ogen) in wound healing and infection control. Semin Thromb Hemost. 2022 Mar;48(2):174–187. |
|
Elisa Danese |
2019 |
Danese E, Montagnana M, Gelati M, Lippi G. The role of epigenetics in the regulation of hemostatic balance. Semin Thromb Hemost. 2021 Feb;47(1):53–62. |
|
Soracha Ward |
2019 |
Ward S, O'Sullivan JM, O'Donnell JS. The biological significance of von Willebrand Factor O linked glycosylation. Semin Thromb Hemost. 2021 Oct;47(7):855–861. |
|
Jonathan Douxfils |
2019 |
Douxfils J, Morimont L, Bouvy C. Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk. Semin Thromb Hemost. 2020 Nov;46(8):872–886. |
|
Erik Klok |
2019 |
Boon GJAM, Huisman MV, Klok FA. Why, whom, and how to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Semin Thromb Hemost. 2021 Sep;47(6):692–701. |
|
Michelle Lavin |
2019 |
Byrne B, Ryan K, Lavin M. current challenges in the peripartum management of women with von Willebrand disease. Semin Thromb Hemost. 2021 Mar;47(2):217–228. |
|
Deeksha Khialani |
2019 |
Khialani D, Rosendaal F, Vlieg AVH. Hormonal contraceptives and the risk of venous thrombosis. Semin Thromb Hemost. 2020 Nov;46(8):865–871. |
|
Hanny Al-Samkari |
2020 |
Al-Samkari H. Systemic antiangiogenic therapies for bleeding in hereditary hemorrhagic telangiectasia: a practical, evidence-based guide for clinicians. Semin Thromb Hemost. 2022 Jul;48(5):514–528. |
|
Matthias M Engelen |
2020 |
Engelen MM, Vandenbriele C, Balthazar T, Claeys E, Gunst J, Guler I, Jacquemin M, Janssens S, Lorent N, Liesenborghs L, Peerlinck K, Pieters G, Rex S, Sinonquel P, Van der Linden L, Van Laer C, Vos R, Wauters J, Wilmer A, Verhamme P, Vanassche T. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost. 2021 Jun;47(4):362–371. |
|
Ellen Driever |
2020 |
Driever EG, Lisman T. Effects of inflammation on hemostasis in acutely ill patients with liver disease. Semin Thromb Hemost. 2022 Jul;48(5):596–606. |
|
Maria Selvadurai |
2020 |
Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. Semin Thromb Hemost. 2023 Jul;49(5):444–452. doi: 10.1055/s-0043-1761269. Epub 2023 Jan 27. PMID: 36706782. |
|
Gudula Boon |
2021 |
de Jong CMM, Boon GJAM, Le YNJ, Barco S, Siegerink B, Klok FA. The post-venous thromboembolism functional status scale: from call to action to application in research, extension to COVID-19 patients, and its use in clinical practice. Semin Thromb Hemost. 2023 Oct;49(7):764–773. |
|
Hunter B. Moore |
2021 |
Moore HB. Fibrinolysis shutdown and hypofibrinolysis are not synonymous terms: the clinical significance of differentiating low fibrinolytic states. Semin Thromb Hemost. 2023 Jul;49(5):433–443. |
|
Sol Schulman |
2021 |
Park JK, Brake MA, Schulman S. Human genetic variation in F3 and its impact on tissue factor-dependent disease. Semin Thromb Hemost. 2024 Mar;50(2):188–199. |
|
Lauren G. Poole |
2022 |
Capece GE, Luyendyk JP, Poole LG. Fibrinolysis-mediated pathways in acute liver injury. Semin Thromb Hemost. 2024 Jun;50(4):638–647. |
|
Aisling Rehill |
2022 |
Noone D, Preston RJS, Rehill AM. The role of myeloid cells in thromboinflammatory disease. Semin Thromb Hemost. 2024 Oct;50(7):998–1011. |
|
Harvey Roweth |
2022 |
Roweth HG. Platelet contributions to the (pre)metastatic tumor microenvironment. Semin Thromb Hemost. 2024 Apr;50(3):455–461. |
|
Azita H. Talasaz |
2022 |
Talasaz AH, McGonagle B, HajiQasemi M, Ghelichkhan ZA, Sadeghipour P, Rashedi S, Cuker A, Lech T, Goldhaber SZ, Jennings DL, Piazza G, Bikdeli B. Pharmacokinetic and pharmacodynamic interactions between food or herbal products and oral anticoagulants: evidence review, practical recommendations, and knowledge gaps. Semin Thromb Hemost. 2024 Sep 17. doi: 10.1055/s-0044-1790258 (e-pub ahead of print). PMID: 39288907. |
|
Rayna Anjis |
2022 |
Chen Q, Anijs RJS, Verlaan JPL, Scheres LJJ, Klok FA, Cannegieter SC. Novel antidiabetic drugs and risk of venous thromboembolism: a literature review. Semin Thromb Hemost. 2025; doi: 10.1055/a-2546-0353; PMID: 40154507 In press |
|
Steven Grover |
2023 |
Grover SP. Hereditary angioedema and venous thromboembolism: where there's smoke, there's fire. Semin Thromb Hemost. 2025 Apr;51(3):322-328. |
|
Amy Kiskaddon |
2023 |
Kiskaddon AL, Branstetter J, Williams P, Ignjatovic V, Memken A, Wilhoit K, Goldenberg NA. Intravenous direct thrombin inhibitors for acute venous thromboembolism or heparin-induced thrombocytopenia with thrombosis in children: a systematic review of the literature. Semin Thromb Hemost. 2025 Apr;51(3):329-334. |
a It should be noted that, as a condition of the award, Eberhard F. Mammen Young Investigator Awardees are expected to submit a manuscript for publication in Seminars in Thrombosis and Hemostasis. This listing in this table comprises previous awardees who have subsequently provided submissions to the journal, and excludes awardees who have as yet not provided their submissions.
As often occurs with these awards, the current crop of winners reflects a variety of “Young Investigators” at various stages of their careers. Some awardees are just starting out on their journey in science or medicine, while others are better established in their careers and crossing over into the next phase of their life where they will soon no longer be called “young” investigators.
Thomas Kazmirchuck ([Fig. 2]) is the youngest of our award recipients, and is a current post-doctoral fellow at Carleton University, in Ottawa, Canada. He studies AI-assisted drug design, with the goal of developing therapeutics and diagnostics for bleeding disorders, such as platelet-type von Willebrand disease. He previously completed his PhD in Cell and Molecular Biology at Concordia University in Montreal, Canada. Thomas is passionate about bringing scientific communities together (such as drug design and hematology), which has been the focus of his career thus far. In bringing fields together, researchers will inevitably bring in important advancements and discoveries that would be otherwise enigmatic.
André L. Lira da Silva ([Fig. 3]) presented on the topic of computational and biophysical models of coagulation. He holds a degree in Biological Physics from São Paulo State University, with a Master's and PhD in Molecular Biology from the Federal University of São Paulo. His academic research focuses on the blood coagulation system, with an emphasis on the interactions between nanoparticles, plasma proteins, and bacterial components. In his current postdoctoral research program at Oregon Health and Science University, he applies his expertise in molecular biophysics to investigate how bacterial membrane components influence the coagulation system, particularly the contact pathway—a crucial process in the progression of sepsis and disseminated intravascular coagulation.
Rowena Brook ([Fig. 4]) is a published early career clinician-researcher in the field of thrombosis and hemostasis, and a PhD candidate with The University of Melbourne at the Northern Health Clinical School, Australia. She is a recipient of the Heart Foundation Postgraduate Scholarship. Rowena is also a consultant laboratory and clinical hematologist at Northern Health, Australia. Dr Brook's key area of research interest is in the application of global coagulation assays and other novel biomarkers in the prospective prediction of clinical outcomes including arterial and venous thrombosis as well as bleeding in different disease groups. She presented work on hemostasis testing in the presence of a direct oral anticoagulant neutraliser to evaluate for any correlation with VTE recurrence in patients on direct oral anticoagulants.
Nina Borràs ([Fig. 5]) presented her work on the von Willebrand disease (VWD) Clinical and Molecular Profile Project in Spain. She is currently a Deputy Physician at the Congenital Coagulopathies laboratory and Genomic laboratory of the Banc de Sang i Teixits, Barcelona, Spain. She completed her PhD in Human Genetics in 2018, where her studies focused on the application of Next Generation Sequencing technologies to unravel the molecular basis of VWD and explore genotype-phenotype correlations in a large cohort of patients. In her current work, she continues to investigate the genetic mechanisms underlying VWD and other bleeding disorders using cutting-edge molecular tools, including exome sequencing and third-generation sequencing technologies.
Leonardo Liu ([Fig. 6]) gave a presentation related to red blood cells promoting tension-dependent cleavage of von Willebrand factor (VWF) in whole blood under high shear. Dr. Z. Leonardo Liu is an Assistant Professor of Biomedical Engineering at Florida State University. His research integrates hemodynamics, mechanobiology, and AI-powered computing to develop a first-principles-based understanding and treatment for thrombosis and hemostasis. His work in Shear-Induced Platelet Aggregation (SIPA) has won him an ISTH State-of-the-Art Lectureship. His recent work uncovered the overlooked role of red blood cells in promoting VWF cleavage through microrheological effects. Dr. Liu serves as the Co-Chair for the Biorheology Scientific and Standardization Committee (SSC) at ISTH and is the RPTH Recap moderator for thrombosis and AI-related talks.
Vittoria Cammisotto ([Fig. 7]) is a researcher at the “Sapienza” University of Rome, where she holds a Biological Sciences degree and has completed her PhD in “Cardio-Thoraco-Vascular Physiopathology and Imaging. She is also a specialist in “Clinical Pharmacology and Toxicology.” Her scientific interest and experience concern the study of the pathways of platelet activation and NOX2-mediated oxidative stress and the functional modulation of these pathways through pharmacological or nutraceutical approaches. She was honored to be nominated for a “2024 Eberhard F. Mammen Young Investigator Award Nomination” because it could represent an excellent opportunity for her further education and international experience.
All award winners were thrilled to hear that they had been selected to receive an Eberhard F. Mammen Young Investigator award, and provided the following additional commentary:
“The Eberhard F. Mammen Young Investigator Award is meant to distinguish and encourage future leaders within the fields of thrombosis and hemostasis. Thus, I am truly honored to have even be considered for this award. To be one of the 2024 awardees is a remarkable achievement and simply would not be possible without the strong support of my supervisors Dr. Ashkan Golshani (Carleton University, Ottawa, Canada) and Dr. Maha Othman (Queen's University, Kingston, Canada). Simply put, without these two strong forces encouraging my development as a scientist, I'm not sure what I would be doing or where I would be. I would like to express my gratitude to the award selection committee at Seminars in Thrombosis & Hemostasis, who undoubtable had to make difficult decisions when considering all the nominees and high bar for this award. Not only does the 2024 Eberhard F. Mammen Young Investigator Award further solidify that my research involving the intelligent design of peptide theranostics with applications in platelet-type von Willebrand disease is important, but it also serves to encourage the expansion of my research program into the field. I am forever grateful for this career milestone, to my supervisors, and to the STH award committee. I will continue to justify your support and trust in my work and future career.”
-
– Thomas Kazmirchuck ([Fig. 2])
“I am truly humbled and honored to have been awarded a 2024 Eberhard F. Mammen Young Investigator Award, recognizing our lab's research on the complex host–pathogen interactions between bacterial membranes and the contact pathway of coagulation. This work contributes to a deeper understanding of how these interactions influence thromboinflammation and immune responses. I am immensely grateful to the senior editorial board of Seminars in Thrombosis and Hemostasis for this recognition. I also want to express my heartfelt appreciation to my postdoctoral mentor, Dr. Owen McCarty, whose guidance has been invaluable, as well as to our collaborators and the supportive community within the Department of Biomedical Engineering at Oregon Health & Science University. This award serves as a powerful motivation to continue investigating the molecular mechanisms that link infection and inflammation to coagulation, with the goal of uncovering new therapeutic insights for thromboinflammatory disorders.”
-
– André L. Lira da Silva ([Fig. 3])
“I am very honored to have been selected for an Eberhard F. Mammen Young Investigator Award and would like to thank the senior editorial board of Seminars in Thrombosis and Hemostasis for their recognition of our work on the use of global coagulation assays in the prediction of spontaneous major hemorrhage in chronic kidney disease patients. This achievement would not have been possible without the efforts my PhD supervisors and the Northern Health NECTAR research group, support from an Australian Heart Foundation PhD scholarship, and most importantly the participation of our Northern Health patients. I would like to extend my particular thanks to my career mentors Professor Prahlad Ho and Associate Professor Hui Yin Lim for their tireless support. I am humbled to be included amongst the list of past inspiring investigators and am excited to continue my research journey in the field of thrombosis and hemostasis.”
-
– Rowena Brook ([Fig. 4])
“I am deeply honored to receive a 2024 Eberhard F. Mammen Young Investigator Award. This award recognizes our work investigating the molecular and clinical profile, as well as genotype–phenotype correlations, in von Willebrand disease (VWD) in Spain, which was presented at the 2024 International Society on Thrombosis and Hemostasis (ISTH) Congress. I would like to extend my heartfelt gratitude to the senior editorial team of Seminars in Thrombosis and Hemostasis for this esteemed recognition. This achievement would not have been possible without the invaluable support and contributions of many individuals. I would like to express my sincere gratitude to my supervisors and mentors, Dr. Francisco Vidal and Dr. Irene Corrales, for their exceptional guidance, unwavering support, and inspiring mentorship throughout this journey. I also extend my deepest thanks to all the investigators involved in the VWD Clinical and Molecular Profile Project in Spain (PCM-EVW-ES) and the patients who participated in this study. This award serves as both an honor and a motivation to continue contributing to the field of molecular genetics in von Willebrand disease.”
-
– Nina Borràs Agustí ([Fig. 5])
“I am deeply honored to receive one of the 2024 Eberhard F. Mammen Young Investigator Awards. My sincere gratitude goes to the senior editorial board of Seminars in Thrombosis and Hemostasis (STH) for recognizing our work on predicting/quantifying red blood cell (RBC)-enhanced von Willebrand factor (VWF) tension-dependent activation. This achievement would not have been possible without the invaluable support and guidance of my PhD advisors and collaborators, especially Professor David N. Ku, whose mentorship has been instrumental to my academic journey. I dedicate this award to my family—my wife Evanna, my daughter Elisha, and my son Feynman—for their unwavering love, patience, and sacrifices as I pursue my independent academic path. Above all, I thank my Lord Jesus Christ for His grace and mercy. This recognition encourages me to continue advancing the emerging field of “rheo-biology” in thrombosis and hemostasis.”
-
– Leonardo Liu ([Fig. 6])
“I am truly honored to be selected as a recipient of a 2024 Eberhard F. Mammen Young Investigator Award. I would like to express my sincere gratitude to the senior editorial board of Seminars in Thrombosis and Hemostasis for this recognition of our research on the role of neutrophil-derived cathepsin G in platelet activation and the potential modulatory effects of gliflozins in patients with type 2 diabetes mellitus (T2DM). This work highlights an important link between inflammation, thrombosis, and cardiovascular risk in T2DM and suggests a novel mechanism by which gliflozins may exert beneficial effects beyond glycemic control. This achievement would not have been possible without the invaluable support of my mentor Prof. Pasquale Pignatelli, the contributions of our collaborators, and the encouragement of colleagues at Sapienza University of Rome. It is a privilege to be recognized alongside such talented researchers in the field of thrombosis and hemostasis. This award serves as a great motivation to continue advancing our understanding of platelet–neutrophil interactions and their impact on cardiovascular complications in diabetes.”
-
– Vittoria Cammisotto ([Fig. 7])
In keeping with previous editorials, I have again updated the Young Investigator Awardees from previous years as well as the outcome of their subsequent submissions to STH, as summarized in [Table 2]. The most recent publications are also listed in the reference list for the benefit of the readership.[3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] I have mentioned several times my personal gratification that most of the papers from earlier years have subsequently appeared in several annual top 100 listings. Of further interest, some of these papers or the young investigators themselves have subsequently won one of the most popular awards (see [Table 1] for a list of prior editorials on these awards).
I continue to look forward to seeing the careers of the current and past Young Investigator Award winners developing over forthcoming years. Very high bars are now established for future Young Investigator Awardees, and I wish all awardees the best of luck to exceed the precedence set by earlier award winners.
#
Conflict of Interest
None declared.
-
References
- 1 Favaloro EJ. 2024 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2024; 50 (07) 919-932
- 2 Favaloro EJ. Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2025; in press
- 3 Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. Semin Thromb Hemost 2023; 49 (05) 444-452
- 4 de Jong CMM, Boon GJAM, Le YNJ, Barco S, Siegerink B, Klok FA. The post-venous thromboembolism functional status scale: from call to action to application in research, extension to COVID-19 patients, and its use in clinical practice. Semin Thromb Hemost 2023; 49 (07) 764-773
- 5 Moore HB. Fibrinolysis shutdown and hypofibrinolysis are not synonymous terms: the clinical significance of differentiating low fibrinolytic states. Semin Thromb Hemost 2023; 49 (05) 433-443
- 6 Park JK, Brake MA, Schulman S. Human genetic variation in F3 and its impact on tissue factor-dependent disease. Semin Thromb Hemost 2024; 50 (02) 188-199
- 7 Capece GE, Luyendyk JP, Poole LG. Fibrinolysis-mediated pathways in acute liver injury. Semin Thromb Hemost 2024; 50 (04) 638-647
- 8 Noone D, Preston RJS, Rehill AM. The role of myeloid cells in thromboinflammatory disease. Semin Thromb Hemost 2024; 50 (07) 998-1011
- 9 Roweth HG. Platelet contributions to the (pre)metastatic tumor microenvironment. Semin Thromb Hemost 2024; 50 (03) 455-461
- 10 Talasaz AH, McGonagle B, HajiQasemi M. et al. Pharmacokinetic and pharmacodynamic interactions between food or herbal products and oral anticoagulants: evidence review, practical recommendations, and knowledge gaps. Semin Thromb Hemost 2024; ( e-pub ahead of print).
- 11 Chen Q. Anijs RJS, Verlaan JPL, Scheres LJJ, Klok FA, Cannegieter SC. Novel antidiabetic drugs and risk of venous thromboembolism: a literature review. Semin Thromb Hemost 2025; Mar 28 . Online ahead of print
- 12 Grover SP. Hereditary angioedema and venous thromboembolism: where there's smoke, there's fire. Semin Thromb Hemost 2025; 51 (03) 322-328
- 13 Kiskaddon AL, Branstetter J, Williams P. et al. Intravenous direct thrombin inhibitors for acute venous thromboembolism or heparin-induced thrombocytopenia with thrombosis in children: a systematic review of the literature. Semin Thromb Hemost 2025; 51 (03) 329-334
Address for correspondence
Publication History
Article published online:
16 April 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Favaloro EJ. 2024 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2024; 50 (07) 919-932
- 2 Favaloro EJ. Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. Semin Thromb Hemost 2025; in press
- 3 Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. Semin Thromb Hemost 2023; 49 (05) 444-452
- 4 de Jong CMM, Boon GJAM, Le YNJ, Barco S, Siegerink B, Klok FA. The post-venous thromboembolism functional status scale: from call to action to application in research, extension to COVID-19 patients, and its use in clinical practice. Semin Thromb Hemost 2023; 49 (07) 764-773
- 5 Moore HB. Fibrinolysis shutdown and hypofibrinolysis are not synonymous terms: the clinical significance of differentiating low fibrinolytic states. Semin Thromb Hemost 2023; 49 (05) 433-443
- 6 Park JK, Brake MA, Schulman S. Human genetic variation in F3 and its impact on tissue factor-dependent disease. Semin Thromb Hemost 2024; 50 (02) 188-199
- 7 Capece GE, Luyendyk JP, Poole LG. Fibrinolysis-mediated pathways in acute liver injury. Semin Thromb Hemost 2024; 50 (04) 638-647
- 8 Noone D, Preston RJS, Rehill AM. The role of myeloid cells in thromboinflammatory disease. Semin Thromb Hemost 2024; 50 (07) 998-1011
- 9 Roweth HG. Platelet contributions to the (pre)metastatic tumor microenvironment. Semin Thromb Hemost 2024; 50 (03) 455-461
- 10 Talasaz AH, McGonagle B, HajiQasemi M. et al. Pharmacokinetic and pharmacodynamic interactions between food or herbal products and oral anticoagulants: evidence review, practical recommendations, and knowledge gaps. Semin Thromb Hemost 2024; ( e-pub ahead of print).
- 11 Chen Q. Anijs RJS, Verlaan JPL, Scheres LJJ, Klok FA, Cannegieter SC. Novel antidiabetic drugs and risk of venous thromboembolism: a literature review. Semin Thromb Hemost 2025; Mar 28 . Online ahead of print
- 12 Grover SP. Hereditary angioedema and venous thromboembolism: where there's smoke, there's fire. Semin Thromb Hemost 2025; 51 (03) 322-328
- 13 Kiskaddon AL, Branstetter J, Williams P. et al. Intravenous direct thrombin inhibitors for acute venous thromboembolism or heparin-induced thrombocytopenia with thrombosis in children: a systematic review of the literature. Semin Thromb Hemost 2025; 51 (03) 329-334